EyePoint is cutting its staff by 53% and stopping clinical trials to change its focus.

Oct 19, 2026, 1:23 PM ETTroubleRead the original at Benzinga

Bad for EYPT

EyePoint's LUCIA trial missed its main vision goal, and it will end wet AMD trials and cut 53% of its workforce. Its DME study met its main goal, and cuts may save $30 million per year, but failed trials and $9 million in one-time costs outweigh those gains.

EYPT · EyePoint Inc.

AI read · Bad for EYPT

The AI's read

The failed vision result removes the reason to keep funding the wet AMD studies. The DME program offers some hope: its mid-stage study met its main goal, and the treatment may reduce injections. But results from 2 large DME studies are not expected until 2027. Cash and expected savings support that work, yet layoffs and severance costs show the scale of the retreat.

Get alerts for EYPT

Follow EyePoint Inc. (EYPT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EYPT

Free on the App Store and Google Play, or on the web.